Protein Engineering Market By Technology (Site-Directed Mutagenesis, Directed Evolution, Phage Display, CRISPR/Cas9), By Application (Drug Development, Industrial Enzymes, Diagnostics, Agriculture, Research & Development), By End-Use Industry (Pharmaceuticals, Biotechnology, Agriculture, Food & Beverage, Chemicals), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Protein Engineering Market was valued at USD 3.6 Billion in 2024-e and will surpass USD 10.1 Billion by 2030; growing at a CAGR of 18.8% during 2025-2030.

The protein engineering market has witnessed rapid growth driven by advancements in biotechnology and genetic engineering technologies. Protein engineering involves the manipulation of protein structures to create proteins with novel properties, which are utilized across various industries, including pharmaceuticals, agriculture, and industrial applications. With the increasing demand for biologics, gene-editing technologies, and the rising applications in drug development and diagnostics, the protein engineering market is expanding at a fast pace. This growth is also fueled by the increased focus on personalized medicine, biologic therapies, and the need for sustainable solutions in agriculture and other sectors.

Site-Directed Mutagenesis Technology is Largest Owing to Its Precision

Site-directed mutagenesis is one of the most widely adopted technologies in protein engineering due to its precision and ability to create specific mutations in a gene. This technique allows scientists to modify an organism's DNA at a particular location, enabling the production of proteins with desired attributes, such as increased stability or enhanced binding capabilities. The ability to introduce a wide range of genetic variations has made site-directed mutagenesis the preferred choice for pharmaceutical and biotechnology companies involved in drug discovery and enzyme development. This technique is often used in the development of biologics and biosimilars, contributing significantly to the market’s growth.

The widespread application of site-directed mutagenesis in drug development, coupled with its efficiency in creating high-yield protein expressions, makes it a dominant technology. It provides better control over protein characteristics, thereby improving therapeutic efficacy. As drug development becomes more personalized, site-directed mutagenesis is expected to remain a pivotal tool in protein engineering, driving its market share.

Drug Development Application is Fastest Growing Owing to Biologic Demand

Drug development is currently the fastest-growing application in the protein engineering market, driven by the rising demand for biologic drugs. Biologic therapeutics, which include monoclonal antibodies, enzymes, and therapeutic proteins, are revolutionizing the treatment of various diseases, including cancer, autoimmune disorders, and genetic conditions. Protein engineering plays a crucial role in developing biologics by optimizing protein stability, efficacy, and specificity. The increasing prevalence of chronic diseases, aging populations, and advancements in personalized medicine are significantly fueling the growth of biologic drugs, thus driving the demand for protein engineering applications in drug development.

As the pharmaceutical industry focuses more on biologics over traditional small-molecule drugs, the need for efficient protein engineering solutions is becoming paramount. With regulatory agencies like the FDA accelerating the approval processes for biologics, the drug development application of protein engineering will continue to grow at an accelerated pace, capturing a significant portion of the market share.

Pharmaceutical Industry is Largest End-Use Industry Owing to Biologic Drug Demand

The pharmaceutical industry is the largest end-use segment in the protein engineering market, as it heavily relies on protein engineering technologies for the development of biologic drugs. Biologics, such as monoclonal antibodies and recombinant proteins, are increasingly becoming a significant part of the pharmaceutical industry’s portfolio. These drugs require precise protein engineering techniques to optimize their structure, function, and production processes. Pharmaceutical companies are leveraging protein engineering to develop novel therapies that address unmet medical needs, such as rare diseases and cancer.

The continuous demand for biologic drugs, combined with advancements in protein expression systems and genetic engineering tools, ensures that the pharmaceutical industry remains the largest contributor to the protein engineering market. As the focus on precision medicine and biologic therapies increases, the pharmaceutical industry will continue to be the dominant end-user of protein engineering solutions.

Asia-Pacific Region is Fastest Growing Owing to Expanding Biotech Sector

The Asia-Pacific region is the fastest-growing in the protein engineering market, driven by the rapid expansion of the biotechnology sector in countries like China, India, and Japan. Increased investments in biotechnology, coupled with supportive government initiatives, have spurred the development of protein engineering technologies in the region. The growth of biopharmaceutical companies, academic research, and innovations in agricultural biotechnology in Asia-Pacific is accelerating the adoption of protein engineering. The rising demand for affordable healthcare and biologic therapies in these countries is further bolstering the growth of protein engineering applications.

As the Asia-Pacific region continues to focus on advancing its biotechnology capabilities, it is poised to become a key player in the global protein engineering market. Increased demand for therapeutic proteins, enzyme-based industrial processes, and genetically modified crops will continue to drive the expansion of protein engineering in the region, making it the fastest-growing market globally.

Competitive Landscape and Leading Companies

The protein engineering market is highly competitive, with numerous established and emerging players driving technological innovations. Key players include Thermo Fisher Scientific, GenScript Biotech Corporation, Agilent Technologies, Roche Diagnostics, and Illumina, among others. These companies focus on advancing protein engineering technologies such as site-directed mutagenesis, CRISPR/Cas9, and directed evolution. Their ability to integrate these technologies into commercial applications like drug development and industrial processes is crucial for maintaining a competitive edge.

Additionally, partnerships, mergers, and acquisitions are prominent in the protein engineering landscape, as companies aim to expand their capabilities and market presence. For example, collaborations between biotechnology companies and pharmaceutical firms are becoming increasingly common to accelerate the development of biologics and personalized medicines. As the demand for protein-based therapies grows, leading companies are expected to continue investing in R&D, acquiring smaller biotech firms, and enhancing their product offerings to stay ahead in this rapidly evolving market.

List of Leading Companies:

• GenScript Biotech Corporation
• Thermo Fisher Scientific Inc.
• Agilent Technologies
• Roche Diagnostics
• Bayer AG
• Eli Lilly and Co.
• Novo Nordisk
• Pfizer Inc.
• Merck & Co., Inc.
• Illumina, Inc.
• Amgen Inc.
• Johnson & Johnson
• Evotec SE
• Bio-Rad Laboratories
• Syngenta AG

Recent Developments:

• Thermo Fisher Scientific acquired The Binding Site Group, a leader in immunodiagnostic products, expanding its capabilities in protein engineering for diagnostics.
• GenScript Biotech introduced advanced CRISPR-Cas9 gene-editing tools to enhance protein engineering capabilities, aiming to accelerate drug development.
• Merck announced a strategic investment in biotechnology startups specializing in protein engineering and novel drug delivery systems.
• Pfizer and Evotec entered a collaboration to accelerate the development of protein therapeutics using advanced protein engineering techniques.
• Amgen received regulatory approval for its newly engineered biologic drug, designed to target specific proteins involved in autoimmune diseases, showcasing protein engineering's critical role in therapeutic advancements.

Report Scope: